GeneThera, Inc. (GTHR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -1.01 Million USD | -25.41% |
| 2020 | -808.31 Thousand USD | -47.98% |
| 2019 | -546.23 Thousand USD | 86.5% |
| 2018 | -4.04 Million USD | -433.8% |
| 2017 | -757.72 Thousand USD | 2.72% |
| 2016 | -778.92 Thousand USD | 28.24% |
| 2015 | -1.08 Million USD | -98.78% |
| 2014 | -546.07 Thousand USD | 48.33% |
| 2013 | -1.05 Million USD | 41.0% |
| 2012 | -1.79 Million USD | -62.74% |
| 2011 | -1.1 Million USD | -127.66% |
| 2010 | -483.53 Thousand USD | 62.8% |
| 2009 | -1.29 Million USD | 34.65% |
| 2008 | -1.98 Million USD | -136.24% |
| 2007 | -841.82 Thousand USD | 43.22% |
| 2006 | -1.48 Million USD | 59.34% |
| 2005 | -3.64 Million USD | 36.66% |
| 2004 | -5.75 Million USD | -136.69% |
| 2003 | -2.43 Million USD | -88.42% |
| 2002 | -1.29 Million USD | -277.21% |
| 2001 | -342.13 Thousand USD | -1626.22% |
| 2000 | -19.82 Thousand USD | 92.25% |
| 1999 | -255.66 Thousand USD | -136.59% |
| 1998 | -108.06 Thousand USD | -80.11% |
| 1997 | -60 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q3 | -126.12 Thousand USD | 15.06% |
| 2022 Q1 | -133.3 Thousand USD | 51.53% |
| 2022 FY | - USD | 100.0% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q2 | -148.49 Thousand USD | -11.4% |
| 2021 Q3 | -243.86 Thousand USD | 14.84% |
| 2021 Q2 | -286.37 Thousand USD | -38.85% |
| 2021 Q4 | -275 Thousand USD | -12.77% |
| 2021 Q1 | -206.24 Thousand USD | -28.07% |
| 2021 FY | -1.01 Million USD | -25.41% |
| 2020 Q1 | -143.35 Thousand USD | 40.06% |
| 2020 Q2 | -195.7 Thousand USD | -36.52% |
| 2020 Q3 | -274.36 Thousand USD | -40.19% |
| 2020 Q4 | -161.03 Thousand USD | 41.31% |
| 2020 FY | -808.31 Thousand USD | -47.98% |
| 2019 Q3 | 36.24 Thousand USD | 124.66% |
| 2019 Q2 | -147 Thousand USD | 12.36% |
| 2019 Q1 | -167.74 Thousand USD | 94.64% |
| 2019 Q4 | -239.14 Thousand USD | -759.81% |
| 2019 FY | -546.23 Thousand USD | 86.5% |
| 2018 Q3 | -349.6 Thousand USD | -0.69% |
| 2018 Q1 | -238.22 Thousand USD | -70.76% |
| 2018 FY | -4.04 Million USD | -433.8% |
| 2018 Q4 | -3.12 Million USD | -795.28% |
| 2018 Q2 | -347.22 Thousand USD | -45.75% |
| 2017 Q3 | -145.87 Thousand USD | 4.42% |
| 2017 FY | -757.72 Thousand USD | 2.72% |
| 2017 Q1 | -319.71 Thousand USD | -1246.27% |
| 2017 Q2 | -152.62 Thousand USD | 52.26% |
| 2017 Q4 | -139.5 Thousand USD | 4.37% |
| 2016 Q1 | -329.46 Thousand USD | -23.32% |
| 2016 FY | -778.92 Thousand USD | 28.24% |
| 2016 Q4 | 27.89 Thousand USD | 111.0% |
| 2016 Q3 | -253.53 Thousand USD | -13.28% |
| 2016 Q2 | -223.81 Thousand USD | 32.07% |
| 2015 FY | -1.08 Million USD | -98.78% |
| 2015 Q1 | -356.46 Thousand USD | -658.53% |
| 2015 Q2 | -157.85 Thousand USD | 55.72% |
| 2015 Q3 | -304 Thousand USD | -92.59% |
| 2015 Q4 | -267.15 Thousand USD | 12.12% |
| 2014 Q3 | -118.76 Thousand USD | 44.53% |
| 2014 Q1 | -165.97 Thousand USD | -21.16% |
| 2014 FY | -546.07 Thousand USD | 48.33% |
| 2014 Q4 | -46.99 Thousand USD | 60.43% |
| 2014 Q2 | -214.09 Thousand USD | -28.99% |
| 2013 Q2 | -282.05 Thousand USD | 1.49% |
| 2013 FY | -1.05 Million USD | 41.0% |
| 2013 Q4 | -136.98 Thousand USD | 61.31% |
| 2013 Q3 | -354.07 Thousand USD | -25.54% |
| 2013 Q1 | -286.3 Thousand USD | 59.38% |
| 2012 Q1 | -514.32 Thousand USD | -168.23% |
| 2012 Q2 | -333.27 Thousand USD | 35.2% |
| 2012 FY | -1.79 Million USD | -62.74% |
| 2012 Q4 | -704.84 Thousand USD | -192.56% |
| 2012 Q3 | -240.92 Thousand USD | 27.71% |
| 2011 FY | -1.1 Million USD | -127.66% |
| 2011 Q1 | -145.19 Thousand USD | 17.77% |
| 2011 Q4 | 753.8 Thousand USD | 149.34% |
| 2011 Q2 | -188.91 Thousand USD | -30.11% |
| 2011 Q3 | -1.52 Million USD | -708.73% |
| 2010 FY | -483.53 Thousand USD | 62.8% |
| 2010 Q1 | -108.52 Thousand USD | -74.99% |
| 2010 Q2 | -89.79 Thousand USD | 17.26% |
| 2010 Q4 | -176.56 Thousand USD | -62.5% |
| 2010 Q3 | -108.65 Thousand USD | -21.01% |
| 2009 Q1 | -313.91 Thousand USD | -120.94% |
| 2009 Q3 | -627.77 Thousand USD | -112.13% |
| 2009 Q2 | -295.93 Thousand USD | 5.73% |
| 2009 Q4 | -62.01 Thousand USD | 90.12% |
| 2009 FY | -1.29 Million USD | 34.65% |
| 2008 Q4 | 1.49 Million USD | 148.06% |
| 2008 Q2 | -176.35 Thousand USD | 7.12% |
| 2008 Q1 | -189.86 Thousand USD | -35.95% |
| 2008 Q3 | -3.11 Million USD | -1668.57% |
| 2008 FY | -1.98 Million USD | -136.24% |
| 2007 Q1 | -219.75 Thousand USD | 58.22% |
| 2007 FY | -841.82 Thousand USD | 43.22% |
| 2007 Q4 | -139.66 Thousand USD | 6.24% |
| 2007 Q3 | -148.96 Thousand USD | 57.42% |
| 2007 Q2 | -349.8 Thousand USD | -59.18% |
| 2006 Q3 | -516.78 Thousand USD | -37.83% |
| 2006 Q4 | -525.91 Thousand USD | -1.77% |
| 2006 FY | -1.48 Million USD | 59.34% |
| 2006 Q1 | -145.99 Thousand USD | 85.61% |
| 2006 Q2 | -374.93 Thousand USD | -156.82% |
| 2005 FY | -3.64 Million USD | 36.66% |
| 2005 Q1 | -2.15 Million USD | -118.92% |
| 2005 Q2 | -316.9 Thousand USD | 85.32% |
| 2005 Q3 | -801.83 Thousand USD | -153.02% |
| 2005 Q4 | -1.01 Million USD | -26.49% |
| 2004 Q4 | 11.4 Million USD | 4440.76% |
| 2004 Q3 | -262.75 Thousand USD | 98.26% |
| 2004 Q2 | -15.14 Million USD | -2256.48% |
| 2004 Q1 | -642.61 Thousand USD | 67.67% |
| 2004 FY | -5.75 Million USD | -136.69% |
| 2003 Q1 | -65.55 Thousand USD | 84.05% |
| 2003 FY | -2.43 Million USD | -88.42% |
| 2003 Q4 | -1.98 Million USD | -892.14% |
| 2003 Q3 | -200.36 Thousand USD | -12.58% |
| 2003 Q2 | -177.97 Thousand USD | -171.51% |
| 2002 Q4 | -411.05 Thousand USD | -94.0% |
| 2002 FY | -1.29 Million USD | -277.21% |
| 2002 Q1 | -268.18 Thousand USD | 21.74% |
| 2002 Q2 | -393.63 Thousand USD | -46.78% |
| 2002 Q3 | -211.88 Thousand USD | 46.17% |
| 2001 FY | -342.13 Thousand USD | -1626.22% |
| 2001 Q4 | -342.69 Thousand USD | -426.22% |
| 2001 Q3 | -65.12 Thousand USD | 66.2% |
| 2001 Q2 | -192.68 Thousand USD | -448.23% |
| 2001 Q1 | -35.14 Thousand USD | -123.56% |
| 2000 Q1 | -59.87 Thousand USD | 76.97% |
| 2000 Q2 | -78.16 Thousand USD | -30.56% |
| 2000 Q3 | -30.98 Thousand USD | 60.36% |
| 2000 Q4 | 149.2 Thousand USD | 581.52% |
| 2000 FY | -19.82 Thousand USD | 92.25% |
| 1999 Q3 | 80 Thousand USD | 900.0% |
| 1999 Q1 | -60 Thousand USD | 0.0% |
| 1999 FY | -255.66 Thousand USD | -136.59% |
| 1999 Q4 | -260 Thousand USD | -425.0% |
| 1999 Q2 | -10 Thousand USD | 83.33% |
| 1998 FY | -108.06 Thousand USD | -80.11% |
| 1998 Q4 | - USD | 0.0% |
| 1997 FY | -60 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.08 Million USD | 100.0% |
| Rebus Holdings, Inc. | -1.02 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.0% |
| Qrons Inc. | -789.34 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -37.64 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -79.46 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 100.0% |
| Mesoblast Limited | -87.95 Million USD | 100.0% |
| Marizyme, Inc. | -65.34 Million USD | 100.0% |
| Genus plc | 7.9 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 100.0% |
| Pharming Group N.V. | -10.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 100.0% |
| ContraFect Corporation | -65.15 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 100.0% |
| IMV Inc. | -36.48 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -380.07 USD | 100.0% |
| ONE Bio Corp. | 8.67 Million USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -2.05 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 100.0% |
| Biomind Labs Inc. | -1.21 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 100.0% |
| GB Sciences, Inc. | -1.36 Million USD | 100.0% |
| Alpha Cognition Inc. | -13.77 Million USD | 100.0% |
| HST Global, Inc. | -146.21 Thousand USD | 100.0% |
| CSL Limited | 2.64 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 100.0% |
| Halberd Corporation | -79.67 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.17 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Resverlogix Corp. | -3.61 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -295.05 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 100.0% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 100.0% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 100.0% |
| AVAX Technologies, Inc. | -6.41 Million USD | 100.0% |
| Zenith Capital Corp. | -10.59 Million USD | 100.0% |
| Genscript Biotech Corporation | -95.47 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| Kadimastem Ltd | -3.3 Million USD | 100.0% |
| Helix BioMedix, Inc. | -1.05 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 100.0% |
| BioStem Technologies, Inc. | -8.48 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 100.0% |
| LadRx Corporation | 400.44 Thousand USD | 100.0% |
| Cell Source, Inc. | -5.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 1.02 Million USD | 100.0% |
| Regen BioPharma, Inc. | 1.02 Million USD | 100.0% |
| NovAccess Global Inc. | -4.76 Million USD | 100.0% |
| Affymax, Inc. | -14.42 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 100.0% |
| Mobile Lads Corp. | -2.26 Million USD | 100.0% |
| CytoDyn Inc. | -49.84 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 100.0% |
| SYBLEU INC | -180.3 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 100.0% |
| International Stem Cell Corporation | -131 Thousand USD | 100.0% |
| Bioxytran, Inc. | -4.28 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.53 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -48.07 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -780.88 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 100.0% |
| Neutra Corp. | -233.46 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 100.0% |
| PureTech Health plc | -65.69 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 100.0% |
| IXICO plc | -1.17 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 100.0% |
| CSL Limited | 2.64 Billion USD | 100.0% |
| Cellectis S.A. | -103.17 Million USD | 100.0% |